Newsroom

New Survey Finds Vast Majority of People Living with Hereditary Angioedema (HAE) Value Efficacy and Specific Correction of C1 INH Deficiency When Choosing an HAE Therapy

KING OF PRUSSIA, Pa. - Reduction in number of attacks is leading factor when evaluating prophylactic therapy

Urban League, CSL Behring Partner to Address Community Needs including Public Health, Workforce Diversity, Leadership Development

KING OF PRUSSIA, Pa. and PHILADELPHIA, Pa. - 6 Urban League Affiliates across U.S. to participate -- starting with Philade…

CSL Behring To Present New Real-World Data on Outcomes Following Acute Coronary Syndrome at American Heart Association Scientific Sessions 2020

KING OF PRUSSIA, Pa. Global biotherapeutics leader reinforces commitment to cardiovascular research: Hosts Learning Studio…

CSL Behring Publishes Design for First-Ever Outcomes Study of ApoA-I to Reduce Risk of Cardiovascular Events in Heart Attack Patients

KING OF PRUSSIA, Pa. The AEGIS-II trial is evaluating the efficacy and safety of CSL112 (apolipoprotein A-1 [human]) duri…

Orphan Drug Designation Granted for CSL Behring’s Investigational Plasma-Derived Hemopexin Therapy for Sickle Cell Disease

KING OF PRUSSIA, Pa. • Both US and European regulators grant special designation • Phase 1 clinical development underw…

CSL Named as One of the World’s Best Employers

KING OF PRUSSIA, Pa. - Forbes Recognizes Global Biotechnology Leader for Fourth Straight Year

CSL’s Broad Response to COVID-19 and Advancements Across the Company’s Strategic Scientific Platforms are the Focus of Annual R&D Day

MELBOURNE, AU and KING OF PRUSSIA, PA • Vaccine, hyperimmune and monoclonal antibodies all in clinical stages as potential…

First Patient Enrolled in NIH Phase 3 Trial to Evaluate Potential COVID-19 Hyperimmune Medicine

Osaka, JAPAN and King of Prussia, Pa., USA • The Alliance’s anti-COVID-19 Hyperimmune Globulin (CoVIg-19) medicine is und…